Genmab A/S Share Price Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
02:30:00 07/11/2026 am IST
|
5-day change | 1st Jan Change | ||
| 53.63 USD | +1.69% |
|
-6.01% | +74.12% |
| 06/11 | Genmab: Strong profit beat but guidance unchanged; time to book profits |  |
| 06/11 | Goldman Sachs raises price target for Genmab to DKK4,500 (4,450), reiterates buy - BN | FW |
| Market Cap | 22TCr 3.33TCr 2.99TCr 2.73TCr 2.49TCr 4.69TCr 3,13000Cr 4.84TCr 33TCr 13TCr 1,67000Cr 12TCr 12TCr 5,27200Cr | P/E 2026 * |
42.3x | P/E 2027 * | 31.1x |
|---|---|---|---|---|---|
| Enterprise Value | 24TCr 3.61TCr 3.23TCr 2.96TCr 2.7TCr 5.08TCr 3,38900Cr 5.24TCr 36TCr 14TCr 1,80800Cr 14TCr 13TCr 5,70800Cr | EV / Sales 2026 * |
8.06x | EV / Sales 2027 * | 6.47x |
| Free-Float |
94.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| GMAB | Delayed | |
CBOE
| GMAB | Real-time | |
|
Börse Stuttgart
| GE91 | Delayed | |
|
Tradegate
| GE91 | Real-time | |
|
Deutsche Boerse AG
| GE91 | Delayed | |
|
Boerse Muenchen
| GE91 | Real-time |
Last Transcript: Genmab A/S
| 1 day | +1.69% | ||
| 1 week | -6.01% | ||
| Current month | -6.01% | ||
| 1 month | +46.33% | ||
| 3 months | +71.62% | ||
| 6 months | +98.19% | ||
| Current year | +74.12% |
| 1 week | 51.22 |  | 56.84 |
| 1 month | 36.12 | | 59.97 |
| Current year | 23.62 | | 59.97 |
| 1 year | 23.62 | | 59.97 |
| 3 years | 17.24 | | 59.97 |
| 5 years | 17.24 | | 59.97 |
| 10 years | 12.1 | | 59.97 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 75 | 01/01/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.69% | -6.01% | - | - | 3.33TCr | |
| -4.83% | +3.51% | +55.00% | +63.79% | 6.59TCr | |
| +0.02% | +1.07% | +11.72% | +75.63% | 5.69TCr | |
| -1.34% | +2.98% | +25.08% | +100.18% | 5.65TCr | |
| +5.09% | +9.89% | +27.19% | +105.85% | 4.65TCr | |
| +2.62% | +1.68% | +29.16% | +35.86% | 4.48TCr | |
| +8.24% | +0.51% | +215.16% | +794.74% | 4.16TCr | |
| -1.86% | +10.13% | +28.14% | +55.48% | 3.53TCr | |
| -2.97% | -9.84% | +90.91% | +73.49% | 3.33TCr | |
| +5.19% | +1.62% | -39.69% | +368.87% | 2.51TCr | |
| Average | +1.19% | +2.65% | +49.18% | +185.99% | 4.51TCr | |
| Weighted average by Cap. | +0.74% | +3.07% | +49.89% | +166.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3TCr 447.23Cr 401.12Cr 366.59Cr 334.64Cr 630.48Cr 42TCr 650.36Cr 4.42TCr 1.76TCr 22TCr 1.68TCr 1.64TCr 71TCr | 3.63TCr 540.79Cr 485.04Cr 443.28Cr 404.65Cr 762.39Cr 51TCr 786.42Cr 5.34TCr 2.13TCr 27TCr 2.03TCr 1.99TCr 86TCr |
| Net income | 513.74Cr 77Cr 69Cr 63Cr 57Cr 108.01Cr 7.2TCr 111.42Cr 757.01Cr 301.86Cr 3.84TCr 287.59Cr 281.42Cr 12TCr | 772.75Cr 115.25Cr 103.37Cr 94Cr 86Cr 162.47Cr 11TCr 167.59Cr 1.14TCr 454.04Cr 5.78TCr 432.58Cr 423.3Cr 18TCr |
| Net Debt | 1.85TCr 275.71Cr 247.28Cr 226Cr 206.3Cr 388.69Cr 26TCr 400.94Cr 2.72TCr 1.09TCr 14TCr 1.03TCr 1.01TCr 44TCr | 1.13TCr 168.33Cr 150.97Cr 137.98Cr 125.95Cr 237.3Cr 16TCr 244.78Cr 1.66TCr 663.15Cr 8.44TCr 631.81Cr 618.26Cr 27TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/26/06 | $53.63 | +1.69% | 78,28,333 |
| 05/26/05 | $52.74 | -4.32% | 44,00,181 |
| 04/26/04 | $55.12 | -0.72% | 42,99,450 |
| 03/26/03 | $55.52 | +1.09% | 30,60,842 |
| 02/26/02 | $54.92 | -3.75% | 44,24,670 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
